Concepedia

James L. Stanton

JL

Statistics

Publications

22

Citations

1.1K

H-Index

19

Active since

1971

Affiliations

Novartis (Switzerland)(Current)

Novartis (United States)

James L. Stanton is an author at Novartis (Switzerland) specializing in pharmacology, medicinal chemistry, and enzyme inhibition.

Publications per year

1971–2005

22

Publications

22

Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme

Jeffrey W. H. Watthey, James L. Stanton, Mahesh Desai et al. · Journal of Medicinal Chemistry · 1985 · 127 citations · Full text

, , +10

Synthesis and biological activity of some transition-state inhibitors of human renin

Walter Fuhrer, Vittorio Rasetti, H. Rüeger et al. · Journal of Medicinal Chemistry · 1988 · 111 citations · Full text

, , +13

Angiotensin converting enzyme inhibitors: 1-glutarylindoline-2-carboxylic acid derivatives

Norbert Gruenfeld, James L. Stanton, Andrew Yuan et al. · Journal of Medicinal Chemistry · 1983 · 76 citations · Full text

, , +16

Angiotensin converting enzyme inhibitors: 1,5-benzothiazepine derivatives

Joel Slade, James L. Stanton, Daniel Ben-David et al. · Journal of Medicinal Chemistry · 1985 · 74 citations · Full text

, , +17

Secondary Amides of (<i>R</i>)-3,3,3-Trifluoro-2-hydroxy-2-methylpropionic Acid as Inhibitors of Pyruvate Dehydrogenase Kinase

Thomas D. Aicher, Robert C. Anderson, Jiaping Gao et al. · Journal of Medicinal Chemistry · 1999 · 68 citations · Full text

, , +11

1–5 of 22